Replies to post #111643 on Savvy Trades and Investments

[wadegarret]

luckygm- GERN

Absolutely holding. The advisory board was almost completely unanimous with their decision today, so FDA approval is almost assured. Also so many Hematologists that chimed in today were impressed with the findings, that I think it has a good chance now for a pharma partner or even buyout. Being that their only competition(Bristol Myers- Reblozyl) is expected to to do $2B+/year in sales by 2027, and GERN has the better drug, I'd say closer to $10 is where I would be looking to sell the stock at this point. Of course I might get tempted to sell some in the $7 area.